Suvretta Capital Management and Affiliates Invest $30M in Veradermics via Pre-Funded Warrants
MANE has more than doubled off its 52-week low of $32 on elevated volume (1.9× avg).
Summary
Suvretta Capital Management and its affiliates invested $30 million in Veradermics through pre-funded warrants as part of a recent private placement, signaling continued institutional support after positive clinical trial results and a successful capital raise.
Key Events · Ownership and Investor Activity · MANE
-
Institutional Investment in Private Placement
Suvretta Capital Management and its affiliated funds acquired 300,000 pre-funded warrants in Veradermics for approximately $30 million.
-
Part of Recent Financing Round
This investment, dated May 1, 2026, was made as part of the company's previously announced private placement and public offering, which raised $388.8 million.
-
Significant Beneficial Ownership Maintained
Suvretta Capital Management and Aaron Cowen now report 9.9% beneficial ownership, while Averill Master Fund holds 8.7%, reflecting continued institutional backing.
Analysis · MANE · Life Sciences
Suvretta Capital Management, along with its affiliated funds Averill Master Fund and Averill Madison Master Fund, has acquired approximately $30 million worth of pre-funded warrants in Veradermics. This investment was part of the company's recent private placement, which closed on May 1, 2026, concurrent with a larger public offering. The acquisition of these warrants, effectively priced at $100 per share (matching the public offering price), demonstrates continued institutional confidence in Veradermics following its positive Phase 2/3 clinical trial data and successful capital raise. This investment, made while the stock trades near its 52-week high, underscores institutional belief in Veradermics' valuation and future prospects. The funds now collectively hold significant stakes, with Suvretta and Aaron Cowen reporting 9.9% beneficial ownership.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 29.2% of the 1498 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MANE was trading at $114.50 on NYSE in the Life Sciences sector, with a market capitalization of approximately $4.7B. The 52-week trading range was $32.00 to $116.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.